Epitalon

Definition

Epitalon is the synthetic tetrapeptide alanine-glutamate-aspartate-glycine, designed in St. Petersburg as a defined analogue of epithalamin, a crude pineal-gland extract studied in Soviet and Russian gerontology since the 1980s.

It is marketed almost entirely on longevity claims — telomere extension chief among them — which makes the distance between its laboratory record and its sales copy the monograph's central subject.

Evidence

The foundational claim is a 2003 report that Epitalon induced telomerase activity and telomere elongation in cultured human fetal fibroblasts ^[1] — a cell-culture observation from the same institute that designed the peptide. The surrounding longevity literature concerns epithalamin, the parent extract, in rodents and fruit flies, not the tetrapeptide in people; a 2025 review collects what has and has not been replicated since ^[2].

No controlled human trial of Epitalon has been published for any endpoint. A buyer weighing a telomere claim against this record is weighing a marketing document against a fibroblast dish.

Lawful access

Epitalon was removed from Category 2 of the interim 503A bulks list in April 2026 without Category 1 listing. In July 2026 the Pharmacy Compounding Advisory Committee voted 7–5, with one abstention, to recommend adding it to the section 503A list — the narrowest recommendation of the meeting, alongside MOTS-c. The vote is advisory; no FDA final rule has issued, and no licensed pharmacy may lawfully compound Epitalon as of August 2026.

Vials sold online today are research-use-only supply, outside pharmacy oversight; the pending page explains the rulemaking still to come.

Related molecules

For a longevity-market contrast with an actual lawful route, see NAD+, which sits in Category 1 and may be compounded on prescription today; MOTS-c shares Epitalon's narrow 7–5 margin and its wait for an FDA final rule.